TABLE 1.
Patient characteristics of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) and Freiburg cohorts for the 12 overlapping clinical features
| GRADS | Freiburg | p-value | |
|---|---|---|---|
| Total | 209 | 50 | |
| Scadding stage | |||
| 0 | 21 (10.1) | 0 (0.0) | 0.02 |
| 1 | 54 (25.8) | 5 (10.0) | |
| 2 | 73 (34.9) | 28 (56.0) | |
| 3 | 27 (12.9) | 11 (22.0) | |
| 4 | 33 (15.8) | 6 (12.0) | |
| NA | 1 (0.5) | 0 (0.0) | |
| Female | 112 (53.6) | 18 (36.0) | 0.04 |
| Age years | 51.6±10.2 26.0–74.9 |
46.3±13.2 21.0–81.0 |
2.9×10−3 |
| FEV1 L | 2.7±1.0 | 2.6±0.9 | 0.497 |
| FEV1 % pred | 85.1±25.3 | 72.9±20.9 | 2.0×10−4 |
| FVC L | 3.6±1.2 | 3.5±1.1 | 0.45 |
| FVC % pred | 86.5±23.0 | 81.4±20.3 | 0.05 |
| FEV 1 /FVC ratio | 0.8±0.1 | 0.8±0.1 | 0.92 |
| Macrophages % | 73.2±32.0 | 54.2±21.2 | 2.6×10−9 |
| Lymphocytes % | 10.5±11.5 | 41.5±21.6 | 1.4×10−19 |
| Neutrophils % | 1.2±2.5 | 2.8±4.4 | 9.0×10−5 |
| Eosinophils % | 0.21±0.95 | 1.08±1.29 | 6.1×10−13 |
Data are presented as n, n (%), mean±SD or range, unless otherwise stated. NA: not available; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.